Coronary Arterial Spasm During Pulsed Field Ablation to Treat Atrial Fibrillation
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F22%3A00009479" target="_blank" >RIV/00023884:_____/22:00009479 - isvavai.cz</a>
Výsledek na webu
<a href="https://pubmed.ncbi.nlm.nih.gov/36134574/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/36134574/</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1161/CIRCULATIONAHA.122.061497" target="_blank" >10.1161/CIRCULATIONAHA.122.061497</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Coronary Arterial Spasm During Pulsed Field Ablation to Treat Atrial Fibrillation
Popis výsledku v původním jazyce
Background: Pulsed field ablation (PFA) has a unique safety profile when used to treat atrial fibrillation, largely related to its preferentiality for myocardial tissue ablation, in particular, esophageal sparing. A pentaspline catheter was the first such PFA system studied clinically for atrial fibrillation ablation; in these initial regulatory trials, the catheter was used for pulmonary vein isolation and left atrial posterior wall ablation. Since its regulatory approval in Europe, in clinical practice, physicians have ablated beyond pulmonary vein isolation and left atrial posterior wall ablation to expanded lesion sets in closer proximity to coronary arteries. This is an unstudied important issue because preclinical and clinical data have raised the potential for coronary arterial spasm. Herein, we studied the vasospastic potential of PFA lesion sets, both remote from and adjacent to coronary arteries.
Název v anglickém jazyce
Coronary Arterial Spasm During Pulsed Field Ablation to Treat Atrial Fibrillation
Popis výsledku anglicky
Background: Pulsed field ablation (PFA) has a unique safety profile when used to treat atrial fibrillation, largely related to its preferentiality for myocardial tissue ablation, in particular, esophageal sparing. A pentaspline catheter was the first such PFA system studied clinically for atrial fibrillation ablation; in these initial regulatory trials, the catheter was used for pulmonary vein isolation and left atrial posterior wall ablation. Since its regulatory approval in Europe, in clinical practice, physicians have ablated beyond pulmonary vein isolation and left atrial posterior wall ablation to expanded lesion sets in closer proximity to coronary arteries. This is an unstudied important issue because preclinical and clinical data have raised the potential for coronary arterial spasm. Herein, we studied the vasospastic potential of PFA lesion sets, both remote from and adjacent to coronary arteries.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30201 - Cardiac and Cardiovascular systems
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2022
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Circulation
ISSN
0009-7322
e-ISSN
—
Svazek periodika
146
Číslo periodika v rámci svazku
24
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
12
Strana od-do
1808-1819
Kód UT WoS článku
000898657500005
EID výsledku v databázi Scopus
2-s2.0-85140266601